摘要
贫血是慢性肾脏病(CKD)的重要并发症之一,促红细胞生成素(EPO)分泌不足和铁缺乏是CKD患者贫血的主要原因,不合理应用红细胞生成刺激剂(ESA)和铁剂,使血红蛋白水平过高、过低,都会导致临床不良事件的发生,本文主要根据2012年改善全球肾脏预后(KDIGO)贫血治疗指南和2014年肾性贫血诊断与治疗中国专家共识,就ESA、铁剂的合理应用等方面进行讨论,提醒临床医师权衡治疗时的风险和获益,合理应用ESA及铁剂,将血红蛋白的水平稳定维持在安全的靶目标范围内,避免贫血治疗带来的不良反应,同时做到贫血治疗的个体化。
Anemia is an important complication of patients with chronic kidney disease （CKD）, whose main causes are reduction of renal erythropoietin （EPO） secretion and iron deficiency. The unreasonable application of erythropoiesis-stimulating agents （ESAs） and iron supplements can make the hemoglobin level too high or too low, which will lead to the occurrence of clinical adverse reactions. This review discussed about the reasonable use of ESAs and iron supplements according to the 2012 Kidney Disease： Improving Global Outcomes （KDIGO） anemia treatment guidelines and the 2014 Chinese experts consensus of diagnosis and treatment of renal anemia, to remind clinicians to evaluate the risk and benefit of the treatment of anemia, to apply ESAs and iron supplements reasonably, to maintain the hemoglobin level in a safe target range, to avoid the side effects of anaemia management, and to individualize the treatment of anaemia.
出处
《中华肾病研究电子杂志》
2014年第5期18-22,共5页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
关键词
慢性肾脏病
贫血
促红细胞生成刺激剂
铁剂
Chronic kidney disease
Anemia
Erythropoiesis- stimulating agent
Iron supplement
